<DOC>
	<DOCNO>NCT00299286</DOCNO>
	<brief_summary>To provide vivo measure activity lapatinib . To assess antiproliferative effect lapatinib breast cancer , ie much lapatinib slow growth cancer cell measure K167 ( marker proliferation ) breast tumours short treatment lapatinib .</brief_summary>
	<brief_title>Short-term Presurgical Study Assess Molecular Predictors Lapatinib 's Effects Primary Breast Cancer</brief_title>
	<detailed_description>Randomised multi centre double blind pre-surgical study woman histological diagnosis breast cancer core biopsy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Patients must histological cytologic diagnosis primary breast cancer tumour size adequate multiple core biopsy Informed sign consent Scheduled primary surgery Expected compliant duration study Age &lt; 80 ECOG performance status 02 ( Karnofsky &gt; 60 % ) Cardiac ejection fraction within institutional range normal measure echocardiogram MUGA scan Eligibility patient receive medication know affect , potential affect activity pharmacokinetics lapatinib determine follow review Trial Coordinator The effect lapatinib develop fetus unknown . For reason , woman childbearing potential must agree use adequate nonhormonal contraception duration study participation . Able swallow retain oral medication . Patients prior diagnosis malignancy except situ disease basal cell carcinoma skin . Patients may receive investigational agent receive concurrent anticancer therapy . In addition , herbal ( alternative ) medicine exclude . Evidence metastatic disease . Use hormonal therapy oral contraceptive hormonal replacement therapy within 4 week study entry . Regular use steroid hormone agent could influence study endpoint History allergic reaction attribute compound similar chemical biologic composition GW572016 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/ social situation would limit compliance study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ki67</keyword>
	<keyword>Molecular</keyword>
	<keyword>antiproliferative</keyword>
</DOC>